Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284616 | 0.91 | — | — | |
| SCHEMBL8773152 | 0.68 | LMNA (0.43) | CYP3A4MEN1KMT2A | |
| SCHEMBL7573395 | 0.67 | FFAR3 (0.38) | FFAR3CYP2C19SMN1; SMN2 | |
| Acetone SCHEMBL7408369 | 0.67 | — | — | |
| SCHEMBL25213839 | 0.66 | FFAR3 (0.72) | FFAR3CYP2C19SMN1; SMN2 | |
| SCHEMBL60503 | 0.66 | FFAR3 (0.72) | FFAR3CYP2C19SMN1; SMN2 | |
| SCHEMBL14627497 | 0.66 | FFAR3 (0.72) | FFAR3CYP2C19SMN1; SMN2 | |
| SCHEMBL18449 | 0.66 | FFAR3 (0.72) | FFAR3CYP2C19SMN1; SMN2 | |
| SCHEMBL13075808 | 0.66 | FFAR3 (0.72) | FFAR3CYP2C19SMN1; SMN2 | |
| SCHEMBL11922843 | 0.66 | FFAR3 (0.72) | FFAR3CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916679-B2 | Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer | Universita′ degli Studi di Modena e Reggio Emilia (IT) | 2014-12-23 | — | — | US | claimed |
| WO-2011103583-A2 | METHODS AND COMPOSITIONS RELATED TO ANTI-ANGIOGENIC PEPTIDES | UNIVERSITY OF CHICAGO (US) | 2011-08-25 | — | — | WO | claimed |
| EP-3628047-A1 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-01 | — | — | EP | disclosed |
| WO-2018204392-A1 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | STANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) | 2018-11-08 | — | — | WO | disclosed |
| EP-3074417-A1 | CXCR ANTAGONISTIC PEPTIDES AND USES THEREOF | Unm.Stc (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015077763-A1 | CXCR ANTAGONISTIC PEPTIDES AND USES THEREOF | STC.UNM (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-01-08 | — | — | US | disclosed |
| WO-2013163431-A1 | DIAGNOSIS AND TREATMENT OF BRAIN TUMOR | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-10-31 | — | — | WO | disclosed |
| US-4481194-A | DIURETICS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | ABCG2, ABCB1, ABCC1 | FFAR3 2031/4885CYP2C19 166/4885CYP3A4 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.